Erigeron breviscapus is a drug that can increase cerebral blood flow, reduce vascular resistance and improve the permeability of blood-brain barrier. Resist platelet aggregation and high viscosity caused by adenosine diphosphate and inhibit thrombosis; Effectively reduce plasma viscosity, hematocrit, platelet aggregation rate and fibrinogen in patients with cerebral infarction, and inhibit abnormal lipoprotein metabolism in patients with ischemic cerebrovascular disease; Increase myocardial nutrient blood volume, improve microcirculation, dilate coronary artery, slow down heart rate, reduce myocardial contractility, reduce peripheral resistance, reduce myocardial oxygen consumption and resist myocardial ischemia. Toxicological studies show that erigeron breviscapus preparation has extensive safety and few adverse reactions in clinical application. Erigeron breviscapus is a basic drug for the treatment of cardiovascular and cerebrovascular diseases. According to the report of World Health Organization (WHO) 1996, the number of people who die of cardiovascular and cerebrovascular diseases worldwide has reached14.6 million every year. The incidence of cardiovascular and cerebrovascular diseases in China is 6%, and there are more than 75 million patients in China. Due to the aging population, the number of new cardiovascular cases in China is 6.5438+0.5 million every year. With the increase of patients with cardiovascular and cerebrovascular diseases, the demand for such drugs has increased.